S&P Futures
3,743.75 +53.50 (+1.45%) Dow Futures
29,911.00 +373.00 (+1.26%) Nasdaq Futures
11,484.50 +198.75 (+1.76%) Russell 2000 Futures
1,745.30 +30.40 (+1.77%) Crude Oil
83.95 +0.32 (+0.38%) Gold
1,717.10 +15.10 (+0.89%)
Amarin Corporation plc (AMRN)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.0900 |
| Open | 1.1000 |
| Bid | 0.0000 x 3200 |
| Ask | 0.0000 x 3100 |
| Day's Range | 1.0600 - 1.1500 |
| 52 Week Range | 1.0400 - 5.2400 |
| Volume | |
| Avg. Volume | 3,349,873 |
| Market Cap | 443.325M |
| Beta (5Y Monthly) | 2.02 |
| PE Ratio (TTM) | 560.00 |
| EPS (TTM) | 0.0020 |
| Earnings Date | Aug 03, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.57 |
- GlobeNewswire
Amarin to Present at H.C. Wainwright’s 24th Annual Global Investment Conference
DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is scheduled to participate at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022. H.C. Wainwright 24th Annual Global Investment Conference (September 12-14th, 2022; New York, New York) Date/Time: September 12, 2022, 9:00 a.m. ET/ 1:00 p.m. GMT+1 Webcast: https://journey.ct
- Benzinga
Amarin Touts Positive Data For Its Heart Disease Drug In Current/Former Smokers
Amarin Corporation plc (NASDAQ: AMRN) announced that new REDUCE-IT data show that Vascepa/Vazkepa (icosapent ethyl) significantly reduced cardiovascular (CV) events in patients with a history of smoking. In this post hoc exploratory analysis, icosapent ethyl (IPE) treatment significantly reduced the risk of first and total primary composite events in current/former smokers by 23% and in former smokers by 29%, compared to the placebo. Related: Amarin's New Vascepa Data Shows Significant Reduction
- GlobeNewswire
New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced Cardiovascular Events in Patients Who Are Current or Former Smokers
-- Data Show VASCEPA/VAZKEPA Significantly Reduced First and Total Cardiovascular Events in Combined Current and Former Smokers by 23% and 29% Respectively Relative to Placebo in a Post Hoc Analysis -- -- Data Presented as an Oral Abstract at European Society of Cardiology (ESC) Congress 2022 in Barcelona and Published in EHJ Cardiovascular Pharmacotherapy -- DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 28, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that new RED
